Webinar: The Art of Communicating Your Science and Startups

Join our panelists Otto Pohl of Core Communications and Lori Lennon of Thinkubator Media as they share their expertise. Otto discusses how to think about PR for your startup, from its strategy and purpose to creating a customer conversion funnel optimized to extract the maximum benefit of your media efforts. Questions answered in this session:…

Webinar: Patient Data Licensing, Part 2 | What can we do with the data?

Thank you for joining us for the second part in our Patient Data Licensing Series: What can we do with the data? The panelists, John Plummer of the Vanderbilt Medical Center and Gavin Foltz of Duke University, will review the transfer and protection of patient data via: • Clinical trial agreements • Non-clinical industry-nonprofit agreements…

Webinar: Life Science Term Sheets

Over the past year, tech transfer directors from Columbia, Duke, JHU, Penn, MIT, Stanford, and Yale worked with life science VCs from 5AM, Atlas, Polaris, OUP, RA Capital, and Venrock to create a common set of principles for university startup deal negotiations. These principles were captured in two documents: “Recommendations for Term Sheet Structuring”, covering equity, royalties, milestones, sublicensing, know-how royalties, diligence, and other recommendations for creating win-win outcomes; and “Recommendations for Process Improvements”, with recommendations for structuring the negotiation process itself to avoid unnecessary friction, gain buy-in early, and avoid overly long and painful negotiations.

Webinar: Life Science Corporate Venture Capital

Corporate VCs have played a crucial role in financing life sciences companies for decades, but have you ever wondered what, if anything, makes them different from institutional venture capital funds? Join us for this webinar as we talk to a panel of investors at industry-leading CVC funds to learn more about their strategies, investment criteria, and how they measure success.

Biostar Biotech: Various Cap Table Scenarios for a Hypothetical Biotech Startup

Osage University Partners’ (OUP) Manager Partner Bill Harrington walks through various cap table scenarios of a hypothetical biotech university startup company called ‘Biostar Biotech.’

Bill highlights three different possible financial outcomes for this company’s investors and equity stakeholders, including a successful exit, a down round, and a company failure. A payout waterfall will be analyzed for each scenario, ending with a side-by-side returns comparison.

Webinar: Small Molecule vs Antibody Development Challenges

Therapeutics remain the primary focus for life science venture investments. As we all know, pre-clinical development of therapeutics is complicated, time consuming, and capital intensive. In the early stages of development, multiple aspects of a therapeutic product need to be optimized to enhance its drug-like properties. However, given the limited time and resources in the academic setting, what aspects of development should inventors focus on? Before diving into drug development, inventors should ask themselves: What is feasible in an academic setting? What is valued more by the investors? Should it be performed in-house or be out-sourced? How much would it cost?